Clinical TrialJun 29, 2026, 07:31 AM
BrainsWay Deep TMS Shows 83.5% Response in Comorbid PTSD/MDD
AI Summary
BrainsWay Ltd. announced positive real-world data for its Deep Transcranial Magnetic Stimulation (Deep TMS) in treating patients with comorbid Post-Traumatic Stress Disorder (PTSD) and Major Depressive Disorder (MDD). The study, presented at an industry conference, showed an 83.5% response rate for PTSD symptoms and a 66.6% response rate for depression symptoms. Patients experienced significant reductions in both PTSD and MDD symptom scores.
Key Highlights
- Deep TMS showed an 83.5% response rate for PTSD symptoms (>=50% reduction).
- Patients experienced a mean 52% reduction in PTSD (PCL-5) scores.
- Deep TMS achieved a 66.6% response rate for depression symptoms (>=50% reduction).
- Patients had a 27.3% remission rate and 50% mean reduction in MDD (PHQ-9) scores.
- The retrospective study included 462 patients from 11 clinical sites.
Price Impact
More from BWAY